Cargando…

Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate

BACKGROUND: All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C,which has been proposed as a novel marker of renal dysfunction,is correlated...

Descripción completa

Detalles Bibliográficos
Autores principales: Qing, Xie, Furong, Wang, Yunxia, Liu, Jian, Zhang, Xuping, Wang, Ling, Gao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3473246/
https://www.ncbi.nlm.nih.gov/pubmed/22978689
http://dx.doi.org/10.1186/1475-2840-11-108
_version_ 1782246733861879808
author Qing, Xie
Furong, Wang
Yunxia, Liu
Jian, Zhang
Xuping, Wang
Ling, Gao
author_facet Qing, Xie
Furong, Wang
Yunxia, Liu
Jian, Zhang
Xuping, Wang
Ling, Gao
author_sort Qing, Xie
collection PubMed
description BACKGROUND: All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C,which has been proposed as a novel marker of renal dysfunction,is correlated with mortality in CAD, The purpose of the study was to evaluate whether cystatin C is a potential marker of asymptomatic CAD in MetS patients with normal kidney function. METHODS: A total of 211asymptomatic MetS patients without prior history of CAD patients were included in a cross-sectional study. Patients were divided into MetS with asymptomatic CAD (n = 136) and MetS without CAD (n = 75) groups according to coronary angiograph results. Serum cystatin C levels were measured using particle enhanced immunonephelometric assays. We first assessed whether there is an independent association of cystatin C with the presence and severity of asymptomatic CAD. Then, we investigated the association between cystatin C and other biochemical risk factors for atherosclerosis. RESULTS: Serum cystatin C levels in patients with asymptomatic CAD were significantly higher than those without CAD (P = 0.004). A multiple logistic regression analysis demonstrated cystatin C was independently associated with the presence of asymptomatic CAD (OR = 1.326, 95%CI: 1.086-1.619). On receiver operating characteristics (ROC) analysis, the area under the curve (AUC) was 0.622 (95 % CI: 0543–0.701, P = 0.003), and cystatin C showed a moderate predictive value. Furthermore, cystatin C was independently correlated with Gensini score (standardized β = 0.183, P = 0.007), and serum cystatin C levels increased with the increasing of number of disease vessels (P = 0.005). In a multiple stepwise regression analysis, uric acid (UA)(P < 0.001), body mass index (BMI)(P = 0.002), triglyceride(TG)(P = 0.03), estimated glomerular filtration rate (eGFR)(P < 0.001), and fibrinogen(P = 0.001) were independently associated with cystatin C. CONCLUSIONS: Serum cystatin C in our study was significantly associated with the presence and severity of asymptomatic CAD in MetS patients with normal kidney function, suggesting that cystatin C is probably more than a marker of glomerular filtration rate.
format Online
Article
Text
id pubmed-3473246
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34732462012-10-18 Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate Qing, Xie Furong, Wang Yunxia, Liu Jian, Zhang Xuping, Wang Ling, Gao Cardiovasc Diabetol Original Investigation BACKGROUND: All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C,which has been proposed as a novel marker of renal dysfunction,is correlated with mortality in CAD, The purpose of the study was to evaluate whether cystatin C is a potential marker of asymptomatic CAD in MetS patients with normal kidney function. METHODS: A total of 211asymptomatic MetS patients without prior history of CAD patients were included in a cross-sectional study. Patients were divided into MetS with asymptomatic CAD (n = 136) and MetS without CAD (n = 75) groups according to coronary angiograph results. Serum cystatin C levels were measured using particle enhanced immunonephelometric assays. We first assessed whether there is an independent association of cystatin C with the presence and severity of asymptomatic CAD. Then, we investigated the association between cystatin C and other biochemical risk factors for atherosclerosis. RESULTS: Serum cystatin C levels in patients with asymptomatic CAD were significantly higher than those without CAD (P = 0.004). A multiple logistic regression analysis demonstrated cystatin C was independently associated with the presence of asymptomatic CAD (OR = 1.326, 95%CI: 1.086-1.619). On receiver operating characteristics (ROC) analysis, the area under the curve (AUC) was 0.622 (95 % CI: 0543–0.701, P = 0.003), and cystatin C showed a moderate predictive value. Furthermore, cystatin C was independently correlated with Gensini score (standardized β = 0.183, P = 0.007), and serum cystatin C levels increased with the increasing of number of disease vessels (P = 0.005). In a multiple stepwise regression analysis, uric acid (UA)(P < 0.001), body mass index (BMI)(P = 0.002), triglyceride(TG)(P = 0.03), estimated glomerular filtration rate (eGFR)(P < 0.001), and fibrinogen(P = 0.001) were independently associated with cystatin C. CONCLUSIONS: Serum cystatin C in our study was significantly associated with the presence and severity of asymptomatic CAD in MetS patients with normal kidney function, suggesting that cystatin C is probably more than a marker of glomerular filtration rate. BioMed Central 2012-09-14 /pmc/articles/PMC3473246/ /pubmed/22978689 http://dx.doi.org/10.1186/1475-2840-11-108 Text en Copyright ©2012 Qing et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Qing, Xie
Furong, Wang
Yunxia, Liu
Jian, Zhang
Xuping, Wang
Ling, Gao
Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title_full Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title_fullStr Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title_full_unstemmed Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title_short Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
title_sort cystatin c and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3473246/
https://www.ncbi.nlm.nih.gov/pubmed/22978689
http://dx.doi.org/10.1186/1475-2840-11-108
work_keys_str_mv AT qingxie cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate
AT furongwang cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate
AT yunxialiu cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate
AT jianzhang cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate
AT xupingwang cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate
AT linggao cystatincandasymptomaticcoronaryarterydiseaseinpatientswithmetabolicsyndromeandnormalglomerularfiltrationrate